Semaglutide Dosing
An educational resource focused specifically on semaglutide dosing — the standard FDA-approved titration schedule (Ozempic and Wegovy), the research-protocol equivalents, side-effect-driven dose adjustments, and the practical mechanics of running a clean semaglutide protocol.
On This Page
About Semaglutide Dosing
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk and approved by the FDA for type 2 diabetes (Ozempic, 2017), chronic weight management (Wegovy, 2021), oral type 2 diabetes (Rybelsus, 2019), and most recently for cardiovascular risk reduction in patients with established cardiovascular disease and overweight or obesity (2024). It is one of the most clinically validated peptide therapeutics in modern medicine, with phase-3 outcome data spanning weight loss, glycemic control, and major adverse cardiovascular events (MACE).
Semaglutide is dosed once weekly because of its ~7-day half-life, achieved through a fatty-acid side chain that drives albumin binding and slows clearance. The dosing schedule is not optional or variable — it is highly structured, with a stepwise titration designed to minimize gastrointestinal side effects while reaching the therapeutic target dose. This page focuses on the dosing protocol itself: the FDA-approved titration, the research-protocol equivalents, common deviations, and how to handle side-effect-driven dose modifications.
The dosing protocol matters because semaglutide is unforgiving when titrated too quickly. Skipping titration steps to chase faster weight loss is one of the most common reasons protocols fail — not because semaglutide stops working, but because the side-effect burden becomes intolerable and the user discontinues. The standard titration is conservative on purpose.
History & Discovery
GLP-1 was identified in the 1980s as one of the incretin hormones — gut peptides that amplify insulin secretion in response to oral glucose. The clinical translation took decades because native GLP-1's minute-scale half-life made it impractical as a drug. Exenatide (Byetta), the first approved GLP-1 agonist (2005), was a synthetic version of exendin-4 from Gila monster saliva — naturally resistant to DPP-4 degradation but still requiring twice-daily dosing.
Liraglutide (Victoza, 2010; Saxenda for obesity, 2014) extended the half-life via a single fatty-acid acylation, enabling once-daily dosing. Semaglutide, developed at Novo Nordisk and approved as Ozempic in 2017, took the acylation strategy further with a longer linker and a C18 diacid chain — extending the half-life to once-weekly.
The Wegovy approval (2021) followed the STEP-1 trial, which showed a mean weight loss of 14.9% at 68 weeks on 2.4 mg weekly versus 2.4% on placebo. This was the first GLP-1 obesity result that approached the magnitude of bariatric surgery in a meaningful subset of responders, and it triggered the global semaglutide demand spike that has shaped supply, pricing, and compounding-pharmacy regulation ever since.
The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight/obesity — extending semaglutide beyond its diabetes and weight-loss indications into cardiovascular risk reduction. The 2024 FDA label expansion reflected this data.
Semaglutide remained on the FDA drug shortage list from 2022 through early 2025, which legally permitted compounding pharmacies to produce semaglutide for patients during the shortage. The shortage was officially resolved in February 2025, which materially restricted compounded semaglutide access and shifted the supply landscape back toward branded Wegovy and Ozempic and toward research-chemical sourcing for non-clinical use.
Mechanism of Action
Semaglutide binds the GLP-1 receptor with high affinity and signals through Gαs-coupled cAMP/PKA pathways. The four mechanistic effects relevant to dosing are: glucose-dependent insulin secretion (the antidiabetic effect), glucagon suppression (also glucose-dependent), delayed gastric emptying (the source of most GI side effects and a substantial contributor to satiety), and direct CNS appetite suppression via GLP-1 receptors in the hypothalamus and brainstem.
The fatty-acid side chain on semaglutide (a C18 diacid linker) is what allows once-weekly dosing. It binds albumin, dramatically slowing renal clearance and DPP-4 degradation. Native GLP-1 has a half-life measured in minutes; semaglutide's is approximately a week. This is why weekly dosing on a fixed day of the week is the standard — and why missed doses can be 'caught up' within a few days but not at the end of the week.
Steady-state concentrations are reached at approximately 4–5 weeks per dose level. This is the pharmacokinetic justification for the standard 4-week titration interval — each step approaches steady state before the next escalation, allowing GI tolerance to develop progressively.
Glucose-dependent insulin secretion is the reason semaglutide does not typically cause hypoglycemia in people without diabetes — at normal blood glucose, the insulinotropic effect drops off. Hypoglycemia risk increases when semaglutide is combined with insulin or sulfonylureas in diabetic patients.
Pharmacokinetics
| Half-life | ~7 days (165 hours) |
| Time to steady state | 4–5 weeks per dose level |
| Bioavailability (subcutaneous) | ~89% |
| Time to peak (Tmax) | 1–3 days post-injection |
| Route | Subcutaneous (Wegovy/Ozempic) · Oral (Rybelsus, ~1% bioavailability) |
| Dosing interval | Once weekly, same day each week |
| Missed-dose window | Within 5 days of scheduled day; otherwise skip and resume normal schedule |
Research Use Cases
Wegovy Titration Protocol — Chronic Weight Management
The FDA-approved Wegovy titration is the reference protocol for weight management: 0.25 mg weekly for 4 weeks → 0.5 mg for 4 weeks → 1.0 mg for 4 weeks → 1.7 mg for 4 weeks → 2.4 mg as the maintenance dose. Total titration period is 16 weeks before reaching target. This is the schedule with the cleanest tolerability data and the lowest discontinuation rate.
Ozempic Titration Protocol — Type 2 Diabetes
The Ozempic schedule starts identically — 0.25 mg for 4 weeks → 0.5 mg — but the maintenance doses are 0.5 mg, 1.0 mg, and 2.0 mg (the maximum on the T2D label). The 0.25 mg starting dose is for tolerability only; it is not a therapeutic dose for glycemic control or weight loss.
Slow-Titration Protocol — High-GI-Sensitivity Subjects
For subjects who experience significant GI side effects on the standard titration, a 6-week or 8-week interval between dose escalations (instead of 4 weeks) is a common research adjustment. The total titration time extends to 24–32 weeks, but tolerability and adherence improve substantially.
Half-Step Titration — Micro-Dosing Between Standard Steps
Some research protocols introduce half-steps between standard doses (e.g., 0.375 mg between 0.25 and 0.5; 0.75 mg between 0.5 and 1.0) to smooth the GI burden of each escalation. This requires careful dose-volume calculation but is a common practical adjustment in the research community.
Maintenance Dose Below 2.4 mg — 'Lowest Effective Dose' Strategy
Not every research subject reaches or requires the 2.4 mg target dose. A meaningful fraction achieves their endpoint at 1.0 mg or 1.7 mg and remains there indefinitely. The Wegovy label explicitly permits indefinite maintenance at 1.7 mg if 2.4 mg is not tolerated.
Post-Maintenance Tapering and Discontinuation
Discontinuation of semaglutide is associated with weight regain (the STEP-4 trial showed approximately two-thirds of weight loss regained within a year of discontinuation). Some research protocols explore extended tapering schedules — stepping back down through dose levels — but the literature on whether tapering versus abrupt discontinuation affects regain is limited.
Research Dosing Reference
Wegovy Standard Titration (FDA-approved, weight management)
16-week titration to reach the 2.4 mg target. The cleanest schedule for tolerability and the reference protocol for weight management research.
Ozempic Standard Titration (FDA-approved, T2D)
0.25 mg is a tolerability dose only — not therapeutic. T2D maintenance options: 0.5, 1.0, or 2.0 mg depending on glycemic response.
Slow Titration (every 6–8 weeks)
For subjects with significant GI burden on the standard schedule. Total titration extends to 24–32 weeks; adherence improves materially.
Half-Step Titration
Smaller increments, smoother GI tolerability. Requires careful volume calculation and is most practical with reconstituted research-grade material where dose volume is flexible.
Lowest Effective Dose Maintenance
Once a weight-loss or glycemic endpoint is achieved, maintenance can continue at the dose that produced the response — not necessarily 2.4 mg. The Wegovy label explicitly permits indefinite 1.7 mg maintenance.
Stacking & Combinations
Semaglutide + Cagrilintide (CagriSema research stack)
Cagrilintide is a long-acting amylin analog. The CagriSema combination — semaglutide + cagrilintide once weekly — has shown additive weight-loss effects in phase 2 trials (around 17% mean weight loss at 32 weeks) and is in late-stage development at Novo Nordisk. The mechanistic complementarity is between GLP-1 (incretin/appetite) and amylin (post-prandial satiety/gastric emptying).
Semaglutide + Tesofensine (research stack)
Tesofensine is a triple monoamine reuptake inhibitor with substantial weight-loss effects in clinical trials. The combination with semaglutide layers a CNS appetite-suppression mechanism on top of the GLP-1 axis. Not a clinical-trial-validated combination; a research configuration.
Semaglutide + Tesamorelin
Pairs GLP-1-mediated weight loss with GH-axis-mediated visceral fat reduction. Useful in research configurations targeting metabolic-syndrome endpoints where visceral adiposity is the specific concern. Tesamorelin's HIV-lipodystrophy approval establishes its visceral-fat selectivity.
Semaglutide + MOTS-c (metabolic stack)
Adds AMPK-mediated insulin sensitization (MOTS-c) to GLP-1 signaling. Mechanistically complementary at the metabolic-flexibility layer; commonly seen in research-community stacks targeting insulin sensitivity in addition to weight loss.
Semaglutide + Resistance Training & Adequate Protein
Not a peptide stack, but the most important practical co-intervention. Semaglutide-induced weight loss includes lean-mass loss. Resistance training (3+ sessions/week) and adequate protein intake (1.6–2.2 g/kg) are the standard mitigations and substantially affect body-composition outcomes.
Side Effect Profile
Common / Mild-to-Moderate
- •Nausea (the dominant side effect — affects 30–50% at higher dose levels, typically improving with continued exposure)
- •Constipation and/or diarrhea (often alternating)
- •Fatigue, particularly in the first 1–2 weeks at each new dose level
- •Reduced appetite (intended; can become excessive at higher doses)
- •Injection-site reactions (mild, transient)
- •Heartburn / acid reflux (related to delayed gastric emptying)
- •Dehydration secondary to reduced food and fluid intake
Serious / Less Common
- •Acute pancreatitis (rare; requires immediate discontinuation and medical evaluation)
- •Gallbladder events (cholelithiasis, cholecystitis) — risk associated with rapid weight loss and direct GLP-1 effects on gallbladder motility
- •Severe gastroparesis (rare; concerning if persistent and not improving)
- •Acute kidney injury secondary to severe dehydration from GI side effects
- •Thyroid C-cell tumors (rodent boxed warning; human relevance unestablished but contraindicated in MEN-2 syndrome and personal/family medullary thyroid carcinoma history)
- •Hypoglycemia when combined with insulin or sulfonylureas in diabetic patients
The single most important practical lever for managing semaglutide side effects is the titration schedule. Most subjects who discontinue semaglutide do so because of GI burden, and most of that GI burden is a function of escalating too quickly. Slowing the titration to 6–8 weeks per step, or introducing half-steps, resolves the majority of tolerability issues. Hydration, meal timing (smaller portions, slower eating), and dietary composition (lower fat, lower volume) also have substantial effects on day-to-day tolerability.
Storage & Reconstitution
- Pre-filled pens (Wegovy, Ozempic): refrigerate at 2–8°C until first use; after first use, the pen can be stored at room temperature (up to 30°C) for up to 28 days. Do not freeze.
- Lyophilized research vials: store refrigerated at 2–8°C; long-term storage at -20°C extends shelf life. Stable at room temperature for short shipping intervals.
- Reconstitute lyophilized semaglutide with bacteriostatic water for injection. Common preparation: 5 mg semaglutide in 2 mL BAC water = 2.5 mg/mL — a convenient concentration for drawing 0.1 mL = 0.25 mg, 0.2 mL = 0.5 mL, etc.
- Inject the BAC water against the vial wall slowly. Swirl gently. Do not shake — semaglutide is amphipathic and will foam.
- Reconstituted semaglutide is stable refrigerated for approximately 30+ days for research purposes. Some research handling guides extend this to 60 days based on stability data, though the conservative 28–30 day window is standard.
- Use 31G insulin syringes for subcutaneous injection. Rotate sites (abdomen, thigh, upper arm) to avoid lipohypertrophy.
- Pick a fixed day of the week and inject on that day. Consistency on day-of-week is more important than consistency on time-of-day, given the ~7-day half-life.
Key Studies & Trial Data
STEP 1 — Semaglutide 2.4 mg in obesity (no diabetes)
The Wegovy registrational trial. 1,961 participants without diabetes; 68 weeks of treatment. Mean weight loss of 14.9% on semaglutide 2.4 mg vs 2.4% on placebo. The result that drove the global semaglutide demand spike and the FDA approval for chronic weight management.
Wilding JPH, et al. N Engl J Med. 2021;384(11):989–1002.
STEP 4 — Continued treatment vs withdrawal
Showed that discontinuation of semaglutide after 20 weeks of titration led to substantial weight regain by week 68, while continued treatment maintained and extended weight loss. The clearest published evidence for the chronic-treatment framing of GLP-1 weight management.
Rubino D, et al. JAMA. 2021;325(14):1414–1425.
SELECT — Cardiovascular outcomes in CV disease + overweight/obesity
17,604 patients with established CV disease and BMI ≥27, no diabetes. Semaglutide 2.4 mg reduced the composite primary endpoint (CV death, non-fatal MI, non-fatal stroke) by 20% over a mean follow-up of approximately 40 months. Established semaglutide as a cardiovascular-risk-reduction therapy and triggered the 2024 label expansion.
Lincoff AM, et al. N Engl J Med. 2023;389(24):2221–2232.
SUSTAIN 6 — CV outcomes in T2D
The first major CV outcomes trial for semaglutide, in type 2 diabetes. Demonstrated a significant reduction in MACE in T2D patients at high cardiovascular risk and supported the broader case for GLP-1 cardiovascular benefit.
Marso SP, et al. N Engl J Med. 2016;375(19):1834–1844.
STEP 8 — Semaglutide vs liraglutide for weight loss
Head-to-head comparison of semaglutide 2.4 mg weekly vs liraglutide 3.0 mg daily in adults with overweight or obesity without diabetes. Semaglutide produced significantly greater weight loss (15.8% vs 6.4%) at 68 weeks, supporting the once-weekly semaglutide as the dominant GLP-1 for weight management.
Rubino DM, et al. JAMA. 2022;327(2):138–150.
Comparisons & Deep Dives
In-depth articles on Peptide Basics that compare Semaglutide Dosing to related compounds and expand on its mechanism and use.
Tirzepatide vs Semaglutide
Direct comparison of the two leading incretin therapies — semaglutide (GLP-1 only) versus tirzepatide (GLP-1 + GIP). Important context for choosing between them.
Why Semaglutide Doesn't Work for Some People
Practical breakdown of the most common reasons semaglutide protocols underperform — too-fast titration, inadequate dose, missing nutrition and training adjuncts, and discontinuation patterns.
How GLP-1 Works for Weight Loss
The mechanistic explainer for the GLP-1 class — useful background on why semaglutide produces the appetite, satiety, and metabolic effects it does.
Best Peptides for Weight Loss
Where semaglutide sits in the broader weight-loss peptide landscape, including AOD-9604, tesofensine, retatrutide, and adipotide.
Insulin Sensitivity & Appetite Peptides
Adjacent context — peptides that act on insulin signaling and appetite regulation, useful when designing combined-mechanism research stacks.
Frequently Asked Questions
Where to Source Research-Grade Semaglutide
Base Peptide
Research-grade lyophilized semaglutide with batch-specific Certificates of Analysis. The standard reference for researchers running semaglutide titration protocols outside the prescription supply chain.
Other reputable suppliers known for batch-specific Certificates of Analysis:
Want a deeper, ongoing reference? Peptide Basics maintains a comprehensive resource on semaglutide alongside calculators, reconstitution guides, and a database of 60+ research peptides.
Read more on Peptide Basics